Effect of statins combined or not combined with metformin on polycystic ovary syndrome: A systematic review and meta‐analysis

Miao, Keyan; Zhou, Hui

doi:10.1111/jog.15301

Cited by 6 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another meta-analysis revealed that the statin group experienced a significant drop in total testosterone, free testosterone, androstenedione, DHEAS, LH, the LH-to-FSH ratio, and prolactin. In addition to demonstrating a significant drop in fasting glucose, the insulin sensitivity index, and high-sensitivity C-reactive protein, the study also showed a significant decline in total cholesterol, LDL-C, and TGs in the statin group [ 111 ].…”

Section: Emerging Therapeuticsmentioning

confidence: 99%

Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics

Singh¹,

Pal²,

Shubham³

et al. 2023

JCM

118

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder, typically characterized by anovulation, infertility, obesity, insulin resistance, and polycystic ovaries. Lifestyle or diet, environmental pollutants, genetics, gut dysbiosis, neuroendocrine alterations, and obesity are among the risk factors that predispose females to PCOS. These factors might contribute to upsurging metabolic syndrome by causing hyperinsulinemia, oxidative stress, hyperandrogenism, impaired folliculogenesis, and irregular menstrual cycles. Dysbiosis of gut microbiota may play a pathogenic role in the development of PCOS. The restoration of gut microbiota by probiotics, prebiotics, or a fecal microbiota transplant (FMT) might serve as an innovative, efficient, and noninvasive way to prevent and mitigate PCOS. This review deliberates on the variety of risk factors potentially involved in the etiology, prevalence, and modulation of PCOS, in addition to plausible therapeutic interventions, including miRNA therapy and the eubiosis of gut microbiota, that may help treat and manage PCOS.

show abstract

Section: Emerging Therapeuticsmentioning

confidence: 99%

Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics

Singh¹,

Pal²,

Shubham³

et al. 2023

JCM

118

View full text Add to dashboard Cite

show abstract

“…Results on metformin compared with COCP are shown in Table 3 . Subgroup analyses are shown in Supplementary Tables S1 and S2 ( 23 ), also illustrated in Supplementary Fig. S2 (subgroups according to BMI) ( 23 ), Supplementary Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Subgroup analyses are shown in Supplementary Tables S1 and S2 ( 23 ), also illustrated in Supplementary Fig. S2 (subgroups according to BMI) ( 23 ), Supplementary Fig. S3 (subgroups according to adults/adolescents) ( 23 ), and Supplementary Fig.…”

Section: Resultsmentioning

confidence: 99%

“…S2 (subgroups according to BMI) ( 23 ), Supplementary Fig. S3 (subgroups according to adults/adolescents) ( 23 ), and Supplementary Fig. S4 (subgroups according to COCP with or without CPA) ( 23 ).…”

Section: Resultsmentioning

confidence: 99%

“…Combination treatment (COCP and metformin) compared with COCP monotherapy is presented in Table 4 , with subgroup analysis reported in Supplementary Table S3 and Supplementary Fig. S5 ( 23 ). Results on combination treatment vs metformin monotherapy are presented in Table 5 , with subgroup analysis in Supplementary Table S4 and Supplementary Fig.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

Melin,

Forslund,

Alesi

et al. 2023

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Context Polycystic ovary syndrome (PCOS) is affecting more than every tenth woman. Objective As part of the 2023 International PCOS Guidelines update, comparisons between combined oral contraceptive pills (COCP), metformin and combination treatment were evaluated. Data Sources Ovid Medline, Embase, PsycINFO, All EBM and CINAHL were searched. Study Selection Women with PCOS included in randomized controlled trials (RCT). Data Extraction We calculated mean differences (MD) and 95% confidence intervals (CI) regarding anthropometrics, metabolic and hyperandrogenic outcomes. Meta-analyses and quality assessment using GRADE was performed. Data Synthesis The search identified 1660 publications, 36 RCTs were included. For hirsutism no differences were seen when comparing metformin versus COCP, nor when comparing COCP versus combination treatment with metformin and COCP. Metformin was inferior on free androgen index (FAI) (7.08, 95% CI 4.81; 9.36), sex hormone binding globulin (SHBG) (-118.61 nmol/l, 95% CI -174.46; -62.75) and testosterone (0.48 nmol/l,95% CI 0.32; 0.64) compared with COCP. COCP was inferior for FAI (0.58, 95% CI 0.36; 0.80) and SHBG (-16.61 nmol/L, 95% CI -28.51; -4.71) compared with combination treatment, whereas testosterone did not differ. Metformin lowered insulin (-27.12 pmol/l, 95%CI -40.65; -13.59) and triglycerides (-0.15 mmol/l, 95%CI -0.29; -0.01) compared with COCP. COCP was inferior for insulin (17.03 pmol/l, 95%CI 7.79; 26.26) and insulin resistance (0.44, 95%CI 0.17; 0.70) compared with combination treatment. Conclusions The choice of metformin or COCP treatment should be based on symptoms, noting that there are some biochemical benefits from combination treatment, targeting both major endocrine disturbances seen in PCOS; hyperinsulinemia and hyperandrogenism.

show abstract

Statins for women with polycystic ovary syndrome not actively trying to conceive

Xiong

Fraison

Kolibianaki

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Effect of statins combined or not combined with metformin on polycystic ovary syndrome: A systematic review and meta‐analysis

Cited by 6 publications

References 26 publications

Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics

Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics

Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

Statins for women with polycystic ovary syndrome not actively trying to conceive

Contact Info

Product

Resources

About